{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:58:41Z","timestamp":1760147921177,"version":"build-2065373602"},"reference-count":34,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T00:00:00Z","timestamp":1678579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: We investigated and compared the efficacy of three and five monthly loading regimens of an intravitreal aflibercept injection (IVA) in patients with diabetic macular edema (DME). Materials and Methods: This was a retrospective study that included patients diagnosed with DME and treated with an either three or five monthly aflibercept loading regimen from July 2018 to March 2022. Information on clinical characteristics and changes in the central retinal thickness (CRT) were obtained from medical records. Results: In total, 44 eyes of 44 patients with DME treated with IVA were included in this study, with 30 eyes treated with 3-monthly loadings (three-loading group) and 14 eyes with 5-monthly loadings (five-loading group). The mean CRT significantly decreased from the baseline one month after loading in both the three-loading and five-loading groups (p &lt; 0.001). Four cases were refractory to treatment in the three-loading group, while there were no cases of refractory DME in the five-loading group. The stability rate was significantly higher in the five-loading group at three months after loading (p = 0.033). Conclusions: Five-monthly loading regimens of IVA might be favorable for DME considering the rate of refractory cases, stable duration, and the importance of early responsiveness to IVA in DME.<\/jats:p>","DOI":"10.3390\/medicina59030558","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T05:36:21Z","timestamp":1678685781000},"page":"558","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens"],"prefix":"10.3390","volume":"59","author":[{"given":"Yoo-Ri","family":"Chung","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Ajou University School of Medicine, Suwon 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Love Eye Clinic, Hwaseong 18309, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihwang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ajou University School of Medicine, Suwon 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21561\/jor.2019.4.2.69","article-title":"Proteinuria as a potential biomarker for the efficacy of intravitreal bevacizumab injection in patients with diabetic macular edema","volume":"4","author":"Chung","year":"2019","journal-title":"J. Retina"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4103\/ijo.IJO_1217_18","article-title":"Current management of diabetic tractional retinal detachments","volume":"66","author":"Stewart","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"857380","DOI":"10.1155\/2013\/857380","article-title":"Expression of VEGF-A, Otx homeobox and p53 family genes in proliferative vitreoretinopathy","volume":"2013","author":"Azzolini","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_6","first-page":"Cd007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: A network meta-analysis","volume":"6","author":"Virgili","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajo.2018.07.030","article-title":"Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in Protocol T","volume":"195","author":"Bressler","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.ophtha.2011.02.018","article-title":"The DA VINCI Study: Phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema","volume":"118","author":"Do","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.5301\/ejo.5001053","article-title":"Aflibercept in the treatment of diabetic macular edema: A review and consensus paper","volume":"27","author":"Avitabile","year":"2017","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","article-title":"Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods","volume":"27","author":"Sorour","year":"2023","journal-title":"Surv. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ophtha.2014.02.023","article-title":"Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: The IN\u2022OCT consensus","volume":"121","author":"Staurenghi","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bjo.86.7.716","article-title":"Visual impairment and blindness in Europe and their prevention","volume":"86","author":"Kocur","year":"2002","journal-title":"Br. J. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000315156","article-title":"Diagnosis of macular edema","volume":"224","author":"Coscas","year":"2010","journal-title":"Ophthalmologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: A unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"ref_20","first-page":"2156273","article-title":"Diabetic macular edema pathophysiology: Vasogenic versus inflammatory","volume":"2016","author":"Verges","year":"2016","journal-title":"J. Diabetes Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","article-title":"Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting","volume":"232","author":"Starr","year":"2021","journal-title":"Am. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41433-021-01672-1","article-title":"Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents","volume":"36","author":"Wang","year":"2022","journal-title":"Eye"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1177\/1060028020904358","article-title":"Efficacy of conversion to aflibercept for diabetic macular edema previously refractory to bevacizumab or ranibizumab: A meta-analysis of high-quality nonrandomized studies","volume":"54","author":"Xiao","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"NP31","DOI":"10.1177\/11206721211004391","article-title":"Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy","volume":"32","author":"Wilkins","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22030","DOI":"10.1038\/s41598-020-78954-3","article-title":"Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s12325-022-02119-z","article-title":"Dosing regimens of intravitreal aflibercept for diabetic macular edema beyond the first rear: VIOLET, a prospective randomized trial","volume":"39","author":"Garweg","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s10384-021-00820-0","article-title":"Treat-and-extend therapy with aflibercept for diabetic macular edema: A prospective clinical trial","volume":"65","author":"Hirano","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.2174\/1381612828666220425101030","article-title":"Safety and outcomes of intravitreal aflibercept in diabetic macular edema\u2014A systematic review","volume":"28","author":"Dascalu","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/ijo.IJO_459_20","article-title":"One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders","volume":"69","author":"Salimi","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00417-022-05703-9","article-title":"Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes","volume":"260","author":"Sugimoto","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/OPTH.S237586","article-title":"Two year visual acuity and structural outcomes in patients with diabetic macular oedema treated with intravitreal aflibercept\u2014A retrospective cohort study","volume":"14","author":"Kern","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3928\/23258160-20200326-04","article-title":"Impact of systemic dipeptidyl peptidase-4 inhibitor use in diabetic macular edema","volume":"51","author":"Rahimy","year":"2020","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/558\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:53:09Z","timestamp":1760122389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,12]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["medicina59030558"],"URL":"https:\/\/doi.org\/10.3390\/medicina59030558","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,3,12]]}}}